New Roles for Immunotherapies and Targeted Agents in Small-Cell Lung Cancer

Optimize care of your patients with SCLC by exploring this comprehensive program designed to keep you abreast of the latest treatment strategies including an interactive module downloadable slideset short expert commentaries and a case-based video module.

Share

Program Content

Activities

Immunotherapy for SCLC
My Thoughts on the Evolving Role of Immunotherapy for SCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 04, 2019

Expires: April 02, 2020

SCLC at ASCO 2019
My Thoughts on the Latest Developments in Small-cell Lung Cancer From ASCO 2019
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 25, 2019

Expires: June 23, 2020

Activities

SCLC Care in 2019: Slideset
Optimizing Management of SCLC in 2019
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 29, 2019

Expires: July 27, 2020

Activities

Immunotherapy in SCLC
A New Era of Immunotherapy in Small-Cell Lung Cancer
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: August 08, 2019

Expires: August 07, 2020

Faculty

cover img faculity

Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

cover img faculity

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

cover img faculity

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech TEXT Only